These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 10191234)

  • 41. Autologous neutralizing antibodies and viral load in HIV-2-infected individuals.
    Tamalet C; Simon F; Dhiver C; Matheron S; de Micco P; Gastao JA; Brun-Vézinet F
    AIDS; 1995 Jan; 9(1):90-1. PubMed ID: 7893447
    [No Abstract]   [Full Text] [Related]  

  • 42. Neutralizing and infection-enhancing antibody responses to human immunodeficiency virus type 1 in long-term nonprogressors.
    Montefiori DC; Pantaleo G; Fink LM; Zhou JT; Zhou JY; Bilska M; Miralles GD; Fauci AS
    J Infect Dis; 1996 Jan; 173(1):60-7. PubMed ID: 8537683
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Virion-bound ICAM-1 and activated LFA-1: a combination of factors conferring resistance to neutralization by sera from human immunodeficiency virus type 1-infected individuals independently of the disease status and phase.
    Losier M; Fortin JF; Cantin R; Bergeron MG; Tremblay MJ
    Clin Immunol; 2003 Aug; 108(2):111-8. PubMed ID: 12921757
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A longitudinal assessment of autologous neutralizing antibodies in children perinatally infected with human immunodeficiency virus type 1.
    Geffin R; Hutto C; Andrew C; Scott GB
    Virology; 2003 Jun; 310(2):207-15. PubMed ID: 12781708
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Mother-to-child transmission of human immunodeficiency virus type 1: correlation with neutralizing antibodies against primary isolates.
    Scarlatti G; Albert J; Rossi P; Hodara V; Biraghi P; Muggiasca L; Fenyö EM
    J Infect Dis; 1993 Jul; 168(1):207-10. PubMed ID: 8515110
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Homotypic antibody responses to fresh clinical isolates of human immunodeficiency virus.
    Montefiori DC; Zhou IY; Barnes B; Lake D; Hersh EM; Masuho Y; Lefkowitz LB
    Virology; 1991 Jun; 182(2):635-43. PubMed ID: 1708933
    [TBL] [Abstract][Full Text] [Related]  

  • 47. HIV-1 cross-neutralizing antibodies in German HIV-1-infected patients do not correlate with an antibody-binding pattern against different HIV-1 isolates.
    Jurkiewicz E; Petry H; Sutor GC; Lang S; Schedel I; Hunsmann G
    AIDS; 1995 Jan; 9(1):91-3. PubMed ID: 7893448
    [No Abstract]   [Full Text] [Related]  

  • 48. Rapid escape from preserved cross-reactive neutralizing humoral immunity without loss of viral fitness in HIV-1-infected progressors and long-term nonprogressors.
    van Gils MJ; Bunnik EM; Burger JA; Jacob Y; Schweighardt B; Wrin T; Schuitemaker H
    J Virol; 2010 Apr; 84(7):3576-85. PubMed ID: 20071586
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Autologous HIV-1 neutralizing antibodies: emergence of neutralization-resistant escape virus and subsequent development of escape virus neutralizing antibodies.
    Arendrup M; Nielsen C; Hansen JE; Pedersen C; Mathiesen L; Nielsen JO
    J Acquir Immune Defic Syndr (1988); 1992; 5(3):303-7. PubMed ID: 1740756
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Neutralizing antibody responses against autologous and heterologous viruses in acute versus chronic human immunodeficiency virus (HIV) infection: evidence for a constraint on the ability of HIV to completely evade neutralizing antibody responses.
    Deeks SG; Schweighardt B; Wrin T; Galovich J; Hoh R; Sinclair E; Hunt P; McCune JM; Martin JN; Petropoulos CJ; Hecht FM
    J Virol; 2006 Jun; 80(12):6155-64. PubMed ID: 16731954
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Neutralizing antibodies against sequential autologous human immunodeficiency virus type 1 isolates after seroconversion.
    Tsang ML; Evans LA; McQueen P; Hurren L; Byrne C; Penny R; Tindall B; Cooper DA
    J Infect Dis; 1994 Nov; 170(5):1141-7. PubMed ID: 7963706
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Human immunodeficiency virus type 1 elite neutralizers: individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithm.
    Simek MD; Rida W; Priddy FH; Pung P; Carrow E; Laufer DS; Lehrman JK; Boaz M; Tarragona-Fiol T; Miiro G; Birungi J; Pozniak A; McPhee DA; Manigart O; Karita E; Inwoley A; Jaoko W; Dehovitz J; Bekker LG; Pitisuttithum P; Paris R; Walker LM; Poignard P; Wrin T; Fast PE; Burton DR; Koff WC
    J Virol; 2009 Jul; 83(14):7337-48. PubMed ID: 19439467
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Isolate-specific neutralizing antibodies in patients with progressive HIV-1-related disease.
    Von Gegerfelt A; Albert J; Morfeldt-Månson L; Broliden K; Fenyö EM
    Virology; 1991 Nov; 185(1):162-8. PubMed ID: 1926772
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Neutralizing antibodies in slowly progressing HIV-1 infection.
    Schønning K; Nielsen C; Iversen J; Nielsen JO; Hansen JE
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Dec; 10(4):400-7. PubMed ID: 7583435
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Antibody-mediated neutralization of primary isolates of human immunodeficiency virus type 1 in peripheral blood mononuclear cells is not affected by the initial activation state of the cells.
    Zhou JY; Montefiori DC
    J Virol; 1997 Mar; 71(3):2512-7. PubMed ID: 9032392
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Breadth of human immunodeficiency virus-specific neutralizing activity in sera: clustering analysis and association with clinical variables.
    Doria-Rose NA; Klein RM; Daniels MG; O'Dell S; Nason M; Lapedes A; Bhattacharya T; Migueles SA; Wyatt RT; Korber BT; Mascola JR; Connors M
    J Virol; 2010 Feb; 84(3):1631-6. PubMed ID: 19923174
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Resistance to neutralizing antibody and expanded coreceptor usage are associated with human immunodeficiency virus type 1 isolates derived from chimpanzees with pathogenic infections.
    Juompan L; Zhou J; Montefiori DC; Novembre FJ
    AIDS Res Hum Retroviruses; 2001 Dec; 17(18):1705-14. PubMed ID: 11788022
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Augmented serum neutralizing activity against primary human immunodeficiency virus type 1 (HIV-1) isolates in two groups of HIV-1-infected long-term nonprogressors.
    Zhang YJ; Fracasso C; Fiore JR; Björndal A; Angarano G; Gringeri A; Fenyö EM
    J Infect Dis; 1997 Nov; 176(5):1180-7. PubMed ID: 9359717
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Autologous and heterologous neutralizing antibody responses following initial seroconversion in human immunodeficiency virus type 1-infected individuals.
    Moog C; Fleury HJ; Pellegrin I; Kirn A; Aubertin AM
    J Virol; 1997 May; 71(5):3734-41. PubMed ID: 9094648
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Rapid development of isolate-specific neutralizing antibodies after primary HIV-1 infection and consequent emergence of virus variants which resist neutralization by autologous sera.
    Albert J; Abrahamsson B; Nagy K; Aurelius E; Gaines H; Nyström G; Fenyö EM
    AIDS; 1990 Feb; 4(2):107-12. PubMed ID: 2328092
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.